Ana Sayfa
Piyasalar
Grafikler ve Fikirler
Algo
Haberler
Store
Aracı Kurumlar
İndir
Ekonomik Takvim
Alım-Satım Sinyalleri
Web Terminali
Heatmap
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
PBYI
#3121
PUMA BIOTECHNOLOGY INC
7.5
8
USD
+0.13%
Sektör:
Sağlık Hizmetleri
Baz:
USD
Kar Para Birimi:
USD
Günlük Aralık
Yıllık Aralık
Günlük Değişim
+0.13%
Aylık Değişim
+26.33%
6 aylık değişim
+41.95%
Yıllık Değişim
+158.70%
Önceki Kapanış
7.5
7
Open
7.6
0
Bid
Ask
Low
7.5
8
High
7.6
1
Hacim
18
Piyasalar
ABD Borsası
Sağlık Hizmetleri
PBYI
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
40.26 M
41.33 M
46.64 M
48.21 M
49.61 M
50.88 M
—
Valuation ratios
Enterprise value
434.43 M
179.16 M
230.71 M
211.05 M
110.85 M
279.1 M
734.12 M
Price to earnings ratio
—
—
—
10.06
4.92
9.75
24.09
Price to sales ratio
—
—
0.81
0.91
0.65
1.32
3.91
Price to cash flow ratio
—
—
-11.72
7.97
3.85
7.21
21.86
Price to book ratio
—
—
8.59
4.03
1.63
2.31
3.9
Enterprise value to EBITDA ratio
-15.46
31.37
3.68
4.31
2.83
7.56
17.36
Profitability ratios
Return on assets %
-0.25
-0.13
0
0.09
0.14
0.14
0.15
Return on equity %
10.08
11.91
0
0.4
0.33
0.24
0.27
Return on invested capital %
-116.13
4.51
0.4
104.46
128.94
130.27
131.57
Gross margin %
100
74.84
75.84
73.4
72.06
74.53
300.6
Operating margin %
-13.51
0.51
10.4
13.85
13.44
16.33
61.56
EBITDA margin %
-9.42
0.79
13.86
13.15
12.6
15.81
68.6
Net margin %
-26.65
-11.51
0
9.16
13.14
13.62
51.67
Liquidity ratios
Quick ratio
1.25
1.21
1.67
1.5
1.45
1.93
6.6
Current ratio
1.28
1.28
1.73
1.57
1.54
2
6.99
Inventory turnover
—
12.06
9.47
10.8
8.15
8.17
7.06
Asset turnover
0.94
1.08
1.02
1.04
1.04
1.06
1.13
Solvency ratios
Debt to assets ratio
0.44
0.51
0.51
0.34
0.13
0.03
0.23
Debt to equity ratio
-17.92
-47.69
5.29
1.45
0.31
0.05
0.42
Long term debt to total assets ratio
0.34
0.43
0.44
0.28
0.1
0
0.11
Long term debt to total equity ratio
-14.12
-39.69
4.55
1.23
0.24
0
0.21
Per share metrics
Operating cash flow per share
—
—
-0.35
0.57
0.79
0.83
0.83
EBIT per share
—
—
0.53
0.69
0.63
0.74
0.74
EBITDA per share
—
—
0.7
0.65
0.59
0.71
0.86
Total debt per share
—
—
2.54
1.63
0.59
0.12
0.9
Cash per share
—
—
1.04
1.03
1.77
1.81
6.96
Net current asset value per share
—
—
2.99
3.28
3.01
3.21
11.41
Tangible book value per share
—
—
-1.09
-0.16
0.83
1.76
5.29
Working capital per share
—
—
1.26
1.19
1.05
1.61
4.87
Book value per share
—
—
0.48
1.12
1.88
2.57
8.87
Puma Biotechnology Inc
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
Haberler
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
Puma Biotechnology 4Ç 2025: NERLYNX geliri %15 arttı
Puma Biotechnology güçlü 4Ç 2025 sonuçlarını açıkladı
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
Puma Biotechnology, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-02-27
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
Puma Biotech kazancı $0,02 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek
Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates
Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates